항비만약 시장 - 예측(2026-2031년)

The anti-obesity drug market, sustaining a 19.04% CAGR, is anticipated to reach USD 116.381 billion in 2031 from USD 40.898 billion in 2025.

The anti-obesity drug market is positioned for steady growth, propelled by the escalating global prevalence of obesity and its associated health burdens. These pharmaceutical interventions, which function through mechanisms such as appetite suppression and catecholamine release, offer a medically-supported pathway for weight management and sustainable health. The market's expansion is driven by a confluence of demographic, lifestyle, and regulatory factors that underscore the critical need for effective therapeutic solutions.

A primary market driver is the increasing global prevalence of obesity across all age groups, including a concerning rise in childhood obesity. This widespread health issue creates a substantial and growing patient population in need of medical intervention. The demand for anti-obesity medications is further amplified by the serious adverse health effects strongly correlated with obesity. The condition is a significant risk factor for multiple chronic diseases, including type 2 diabetes and various forms of cancer, positioning it as a major contributor to premature mortality worldwide. This direct link to life-threatening comorbidities underscores the therapeutic necessity of anti-obesity pharmacotherapy.

Modern lifestyle patterns represent another significant contributor to market growth. Factors such as prolonged sedentary behavior, particularly in corporate environments, consumption of processed foods, irregular sleep schedules, and chronic stress have created environmental conditions conducive to obesity. The pervasive integration of digital technology into daily life further compounds these sedentary habits. These collective lifestyle shifts have established a sustained demographic base requiring pharmaceutical support for weight management.

Governmental and institutional initiatives are actively shaping the market landscape. International health organizations and national health departments are implementing awareness campaigns and technical frameworks aimed at combating obesity, particularly focusing on protective measures for children. These public health efforts serve to educate populations about weight-related health risks and legitimize obesity as a condition requiring medical management, thereby fostering a more receptive environment for anti-obesity treatments.

North America emerges as the dominant regional market, a status reinforced by high obesity rates and a progressive regulatory framework. The region benefits from multiple FDA approvals for weight management medications designated for long-term use, providing clinicians with a range of therapeutic options. The presence of major pharmaceutical companies, combined with advanced technological infrastructure and substantial research and development activities, further consolidates North America's leadership position in both adoption and innovation within the anti-obesity drug sector.

The market presents significant opportunities for development, particularly through the creation of advanced therapeutic agents that offer improved efficacy and safety profiles. The substantial global mortality attributed to obesity highlights the urgent need for more effective pharmaceutical interventions. However, market growth is tempered by certain restraining factors, including stringent government regulations governing drug approval and usage. Additional challenges include low utilization rates of weight management services and prescribing limitations that restrict use to specific patient populations based on Body Mass Index and comorbidities.

The competitive landscape features specialized pharmaceutical companies such as Currax Pharmaceuticals and GlaxoSmithKline, which market approved products like Contrave(R) and Alli(R). These players are increasingly focusing on personalized treatment approaches and public awareness campaigns that address the varied physiological and behavioral aspects of obesity, reflecting a maturation in how the condition is understood and treated within the medical community.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Anti-Obesity Drugs Market Segmentation:

• By Mechanism of Action
• Peripherally Acting Drugs
• Centrally Acting Drugs
• By Drug Type
• Prescription Drugs
• OTC Drugs
• By Mode of Administration
• Oral
• Injectable
• By End-User
• Adults
• Children & Youngsters
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. ANTI-OBESITY DRUGS MARKET BY MECHANISM OF ACTION

• 5.1. Introduction
• 5.2. Peripherally Acting Drugs
• 5.3. Centrally Acting Drugs

6. ANTI-OBESITY DRUGS MARKET BY DRUG TYPE

• 6.1. Introduction
• 6.2. Prescription Drugs
• 6.3. OTC Drugs

7. ANTI-OBESITY DRUGS MARKET BY MODE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Inectable

8. ANTI-OBESITY DRUGS MARKET BY END-USER

• 8.1. Introduction
• 8.2. Adults
• 8.3. Children & Youngsters

9. ANTI-OBESITY DRUGS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Mechanism of Action
  • 9.2.2. By Type
  • 9.2.3. By Mode of Administration
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Mechanism of Action
  • 9.3.2. By Type
  • 9.3.3. By Mode of Administration
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Mechanism of Action
  • 9.4.2. By Type
  • 9.4.3. By Mode of Administration
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. Germany
    • 9.4.5.2. France
    • 9.4.5.3. United Kingdom
    • 9.4.5.4. Spain
    • 9.4.5.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. By Mechanism of Action
  • 9.5.2. By Type
  • 9.5.3. By Mode of Administration
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Israel
    • 9.5.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. By Mechanism of Action
  • 9.6.2. By Type
  • 9.6.3. By Mode of Administration
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
    • 9.6.5.2. India
    • 9.6.5.3. Japan
    • 9.6.5.4. South Korea
    • 9.6.5.5. Indonesia
    • 9.6.5.6. Thailand
    • 9.6.5.7. Taiwan
    • 9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Currax Pharmaceuticals LLC
• 11.2. GlaxoSmithKline PLC
• 11.3. Novo Nordisk A/S
• 11.4. Pfizer Inc.
• 11.5. Eli Lilly and Company
• 11.6. VIVUS LLC
• 11.7. Boehringer Ingelheim International GmbH
• 11.8. AstraZeneca plc
• 11.9. Rhythm Pharmaceuticals Inc
• 11.10. Amgen Inc

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations